Titan Pharmaceuticals Share Price

TTNP

US8883147055

Market Closed - Nasdaq 01:30:00 27/10/2026 am IST			5-day change	1st Jan Change
0.3640 ^USD	-0.68%		-0.38%	-92.10%

04/25/04	Titan Pharmaceuticals announces closing of merger with Black Titan Corporation	RE
02/25/02	Titan Pharmaceuticals, Inc. Appoints Chay Weei Jye as the Sole Director and Acting Secretary, Effective October 1, 2025	CI

Valuation: Titan Pharmaceuticals

Market Cap	61.32L 54.84L 50.73L 45.93L 85.97L 58Cr 87.38L 6.1Cr 2.41Cr 31Cr 2.3Cr 2.25Cr 97Cr	P/E 2023	-1.11x	P/E 2024	-0.62x
Enterprise Value	33.01L 29.52L 27.31L 24.73L 46.28L 31Cr 47.04L 3.29Cr 1.3Cr 16Cr 1.24Cr 1.21Cr 52Cr	EV / Sales 2023	0.11x	EV / Sales 2024	-
Free-Float	-	Yield 2023 *	-	Yield 2024	-

* Estimated data More valuation ratios

Latest news: Titan Pharmaceuticals

04/25/04	Titan Pharmaceuticals announces closing of merger with Black Titan Corporation	RE
02/25/02	Titan Pharmaceuticals, Inc. Appoints Chay Weei Jye as the Sole Director and Acting Secretary, Effective October 1, 2025	CI
01/25/01	Titan Pharmaceuticals, Inc.(NasdaqCM:TTNP) dropped from NASDAQ Composite Index	CI
01/25/01	Ke Sdn. Bhd. completed the acquisition of Titan Pharmaceuticals, Inc. in a reverse merger transaction.	CI
15/25/15	Titan Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
27/25/27	Titan Pharmaceuticals, Inc. announced that it has received $0.6 million in funding from Blue Harbour Asset Management L.L.C	CI
24/25/24	Titan Pharmaceuticals, Inc. announced that it expects to receive $0.6 million in funding from Blue Harbour Asset Management L.L.C	CI
15/25/15	Titan Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
12/25/12	Titan Pharmaceuticals Announces $1 Million Private Placement Of Convertible Preferred Stock	RE
11/25/11	Titan Pharmaceuticals, Inc. announced that it has received $1 million in funding	CI
02/25/02	Titan Pharmaceuticals, Inc. Appoints Gabriel Loh as an Independent Director and Member of the Audit Committee	CI
29/25/29	Titan Pharmaceuticals, Inc. announced that it expects to receive $1 million in funding	CI
21/25/21	Titan Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI

More news

Analysts' recommendations: Titan Pharmaceuticals

26/22/26	Maxim Downgrades Titan Pharmaceuticals to Hold From Buy	MT
18/21/18	Titan Pharmaceuticals : Maxim Group Upgrades Titan Pharmaceuticals to Buy From Hold, $11 Price Target	MT

More recommendations

Press Releases: Titan Pharmaceuticals

15/25/15	Titan Pharmaceuticals: Q2 Earnings Snapshot	AQ
06/25/06	TITAN PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Titan Pharmaceuticals, Inc. - TTNP	BU
28/25/28	Titan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred Stock	AQ
03/25/03	Titan Pharmaceuticals Announces Filing of Registration Statement for Proposed Business Combination with TalenTec Sdn. Bhd.	AQ
15/25/15	Titan Pharmaceuticals: Q1 Earnings Snapshot	AQ

More press releases

Titan Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. ProNeura offers continuous drug delivery and consists of a small, semi-rigid, flexible implant made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The resulting product is a solid matrix implant that is placed subdermally, normally in the inside part of the upper arm, in a brief procedure using a local anesthetic and is removed in a similar manner at the end of the treatment period. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus. Its product development programs are in non-clinical stages of development.

Employees

Sector

More about the company

Quotes

Date	Price	Change
27/26/27	$0.3640	-0.68%
23/26/23	$0.3665	+1.98%
22/26/22	$0.3594	-6.41%
21/26/21	$0.3840	+4.23%
20/26/20	$0.3684	+5.26%

Delayed Quote Nasdaq

More quotes

3 years	0		14.8
5 years	0		37.6
10 years	0		17,640.02

	2023	2024
Net sales	2L 2L 2L 1L 3L 1.75Cr 3L 18.32L 7L 91.56L 7L 7L 2.9Cr	-
Net income	-55.69L -49.8L -46.07L -41.71L -78.07L -53Cr -79.35L -5.54Cr -2.19Cr -28Cr -2.09Cr -2.05Cr -88Cr	-47.06L -42.08L -38.93L -35.25L -65.97L -45Cr -67.06L -4.68Cr -1.85Cr -23Cr -1.77Cr -1.73Cr -74Cr
Net Debt	-61.95L -55.4L -51.25L -46.4L -86.85L -59Cr -88.27L -6.17Cr -2.44Cr -31Cr -2.33Cr -2.28Cr -98Cr	-28.31L -25.31L -23.42L -21.21L -39.69L -27Cr -40.34L -2.82Cr -1.11Cr -14Cr -1.06Cr -1.04Cr -45Cr

Titan Pharmaceuticals Share Price

Stocks

TTNP

US8883147055

Valuation: Titan Pharmaceuticals

Chart: Titan Pharmaceuticals

Latest news: Titan Pharmaceuticals

Analysts' recommendations: Titan Pharmaceuticals

Press Releases: Titan Pharmaceuticals

Quotes and Performance

Price Extremes

Financials

Company Profile

Quotes

1 day	-0.68%
Current month	-92.10%
Current year	-92.10%